Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 2Withdrawn 1Unknown 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

pembrolizumab 65Nivolumab 58Magnetic Resonance Spectroscopy 53enzalutamide 39Abiraterone Acetate 37Radiosurgery 36Gemcitabine 35Specimen Handling 32Radiotherapy 32Ipilimumab 32Androgen Antagonists 32Prednisone 31apalutamide 28Cisplatin 28Docetaxel 27Leuprolide 26atezolizumab 25Carboplatin 25durvalumab 23cabozantinib 23darolutamide 20acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 19olaparib 18Goserelin 17Radiation 16Gonadotropin-Releasing Hormone 16Biopsy 16gallium 68 PSMA-11 15Pluvicto 15avelumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Propranolol × Genitourinary × Clear all
NCT04848519 2026-02-19

Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma

Emory University

Phase 2 Active not recruiting
6 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡